nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2008

Imaging of integrin αvβ3 expression

verfasst von: Ambros J. Beer, Markus Schwaiger

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

The integrin αvβ3 plays an important role in angiogenesis and tumor metastasis. It is expressed on activated endothelial cells as well as some tumor cells. Therefore it is a promising imaging target as a potential surrogate parameter of angiogenic activity. Molecular imaging of αvβ3 expression could potentially facilitate response evaluation of antiangiogenic drugs (e. g. bevacizumab) or aid in selecting and monitoring patients receiving humanized monoclonal antibody therapies directed against αvβ3 (EMD121974). Therefore many different approaches for imaging of αvβ3 expression have been studied in the recent years, including positron emission tomography (PET), single photon emission tomography (SPECT), magnetic resonance imaging (MRI), optical imaging and ultrasound using targeted microbubbles. While optical imaging techniques lend themselves for preclinical studies, PET and SPECT using the αvβ3 specific tracers [¹⁸F]galacto-RGD and [^99mTc]NC100692 are the only techniques up to now which have been successfully used in patients. The various advantages and disadvantages of several imaging techniques will be discussed in this article.

Ruoslahti, E. (1996). RGD and other recognition sequences for integrins. Annual Review of Cell and Developmental Biology, 12, 697–715.PubMed

Hood, J. D., & Cheresh, D. A. (2002). Role of integrins in cell invasion and migration. Nature Reviews Cancer, 2, 91–100.PubMed

Xiong, J. P., Stehle, T., Zhang, R., et al. (2002). Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg–Gly–Asp ligand. Science, 296, 151–155.PubMed

Cai, W., & Chen, X. (2006). Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anti-Cancer Agents in Medicinal Chemistry, 6, 407–428.PubMed

Hynes, R. O. (2002). A reevaluation of integrins as regulators of angiogenesis. Nature Medicine, 8, 918–921.PubMed

Kerbel, R. S. (2006). Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science, 312, 1171–1175.PubMed

Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335–2342.PubMed

Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., et al. (2007). Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. Journal of Clinical Oncology, 25, 1651–1657.PubMed

Jaffe, C. C. (2006). Measures of response: RECIST, WHO, and new alternatives. Journal of Clinical Oncology, 24, 3245–3251.PubMed

10.

Tortora, G., Melisi, D., & Ciardiello, F. (2004). Angiogenesis: A target for cancer therapy. Current Pharmaceutical Design, 10, 11–26.PubMed

11.

Galbraith, S. M. (2003). Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. British Journal of Radiology, 76, 83–86.

12.

Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. New England Journal of Medicine, 285, 1182–1186.PubMed

13.

Ribatti, D., Vacca, A., & Dammacco, F. (1999). The role of the vascular phase in solid tumor growth: a historical review. Neoplasia, 1, 293–302.PubMed

14.

Risau, W. (1997). Mechanisms of angiogenesis. Nature, 386, 671–674.PubMed

15.

Ellis, L. M., Liu, W., Fan, F., Jung, Y. D., Reinmuth, N., Stoeltzing, O., et al. (2002). Synopsis of angiogenesis inhibitors in oncology. Oncology, 16, 14–22.PubMed

16.

Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249–257.PubMed

17.

Hagedorn, M., & Bikfalvi, A. (2000). Target molecules for anti-angiogenic therapy: From basic research to clinical trials. Critical Reviews in Oncology/Hematology, 34, 89–110.PubMed

18.

Kuwano, M., Fukushi, J., Okamoto, M., Nishie, A., Goto, H., Ishibashi, T., et al. (2001). Angiogenesis factors. Internal Medicine, 40, 565–572.PubMed

19.

Rundhaug, J. E. (2005). Matrix metalloproteinases and angiogenesis. Journal of Cellular and Molecular Medicine, 9, 267–285.PubMed

20.

Eliceiri, B. P., & Cheresh, D. A. (2000). Role of alpha v integrins during angiogenesis. Cancer Journal From Scientific American, 6, 245–249.

21.

Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000). Vascular-specific growth factors and blood vessel formation. Nature, 407, 242–248.PubMed

22.

Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nature Medicine, 6, 389–395.PubMed

23.

Auguste, P., Lemiere, S., & Larrieu-Lahargue, F. (2005). Molecular mechanisms of tumor vascularization. Critical Reviews in Oncology/Hematology, 54(1), 53–61.PubMed

24.

Weber, W. A. (2006). Positron emission tomography as an imaging biomarker. Journal of Clinical Oncology, 24(20), 3282–3292.PubMed

25.

Jaffer, F. A., & Weissleder, R. (2005). Molecular imaging in the clinical arena. JAMA, 293, 855–862.PubMed

26.

Matsumoto, K., Kitamura, K., Mizuta, T., et al. (2006). Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high sensitivity and high resolution PET camera evaluated with the NEMA NU 2-2001 standard. Journal of Nuclear Medicine, 47, 83–90.PubMed

27.

Chatziioannou, A. F. (2005). Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proceedings of the American Thoracic Society, 2, 533–536.PubMed

28.

Haubner, R., Finsinger, D., & Kessler, H. (1997). Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angewandte Chemie International Edition in English, 36, 1374–1389.

29.

Haubner, R., Wester, H. J., Reuning, U., et al. (1999). Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor targeting. Journal of Nuclear Medicine, 40, 1061–1071.PubMed

30.

Haubner, R., Wester, H. J., Weber, W. A., et al. (2001). Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Research, 61, 1781–1785.PubMed

31.

Haubner, R. (2006). αvβ3-Integrin imaging: A new approach to characterise angiogenesis? European Journal of Nuclear Medicine and Molecular Imaging, 33, 54–63.PubMed

32.

Harris, J. M., Martin, N. E., & Modi, M. (2001). PEGylation: A novel process for modifying pharmacokinetics. Clinical Pharmacokinetics, 40, 539–551.PubMed

33.

Chen, X., Park, R., Shahinian, A. H., et al. (2004). Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nuclear Medicine and Biology, 31, 11–19.PubMed

34.

van Hagen, P. M., Breeman, W. A., Bernard, H. F., et al. (2000). Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. International Journal of Cancer, 90, 186–198.

35.

Bach-Gansmo, T., Danielsson, R., Saracco, A., Wilczek, B., Bogsrud, T. V., Fangberget, A., et al. (2006). Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate ^99mTc-NC100692. Journal of Nuclear Medicine, 47(9), 1434–1439.PubMed

36.

Cai, W., Wu, Y., Chen, K., Cao, Q., Tice, D. A., & Chen, X. (2006). In vitro and in vivo characterization of ⁶⁴Cu-labeled Abegrin, a humanized monoclonal antibody against integrin αvβ3. Cancer Research, 66, 9673–9681.PubMed

37.

Haubner, R., Wester, H. J., Burkhart, F., Senekowitsch-Schmidtke, R., Weber, W., Goodman, S. L., et al. (2001). Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. Journal of Nuclear Medicine, 42, 326–336.PubMed

38.

Haubner, R., Kuhnast, B., Mang, C., Weber, W. A., Kessler, H., Wester, H. J., et al. (2004). [¹⁸F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chemistry, 15, 61–69.PubMed

39.

Felding-Habermann, B., Mueller, B. M., Romerdahl, C. A., & Cheresh, D. A. (1992). Involvement of integrin av gene expression in human melanoma tumorigenicity. Journal of Clinical Investigation, 89, 2018–2022.PubMed

40.

Haubner, R., Weber, W. A., Beer, A. J., Vabuliene, E., Reim, D., Sarbia, M., et al. (2005). Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [¹⁸F]Galacto-RGD. PLoS Medicine, 2(3), e70.PubMed

41.

Myoken, Y., Kayada, Y., Okamoto, T., Kan, M., Sato, G. H., & Sato, J. D. (1991). Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proceedings of the National Academy of Sciences of the United States of America, 88, 5818–5823.

42.

Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., & Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808–812.PubMed

43.

Pichler, B., Braumueller, H., Haubner, R., Sakrauski, A. K., Kneilling, M., Senekowitsch-Schmidtke, R., et al. (2002). Monitoring of cellular immunotherapy in RIP1-Tag2 transgenic mice with radiolabelled RGD-peptides. Journal of Nuclear Medicine, 43, 122, (abstract).

44.

Boturyn, D., Coll, J. L., Garanger, E., Favrot, M. C., & Dumy, P. (2004). Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. Journal of the American Chemical Society, 126, 5730–5739.PubMed

45.

Goel, A., Baranowska-Kortylewicz, J., Hinrichs, S. H., Wisecarver, J., Pavlinkova, G., Augustine, S., et al. (2001). ^99mTc-labeled divalent and tetravalent CC49 single-chain Fv’s: Novel imaging agents for rapid in vivo localization of human colon carcinoma. Journal of Nuclear Medicine, 42, 1519–1527.PubMed

46.

Chen, X., Tohme, M., Park, R., Hou, Y., Bading, J. R., & Conti, P. S. (2004). Micro-PET imaging of αvβ3-integrin expression with ¹⁸F-labeled dimeric RGD peptide. Molecular Imaging, 3, 96–104.PubMed

47.

Zhang, X., Xiong, Z., Wu, X., et al. (2006). Quantitative PET imaging of tumor integrin αvβ3 expression with ¹⁸F-FRGD2. Journal of Nuclear Medicine, 47, 113–121.PubMed

48.

Chen, X., Park, R., Tohme, M., Shahinian, A. H., Bading, J. R., & Conti, P. S. (2004). MicroPET and autoradiographic imaging of breast cancer av-integrin expression using ¹⁸F- and ⁶⁴Cu-labeled RGD peptide. Bioconjugate Chemistry, 15, 41–49.PubMed

49.

Chen, X., Hou, Y., Tohme, M., et al. (2004). PEGylated Arg–Gly–Asp peptide: ⁶⁴Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. Journal of Nuclear Medicine, 45, 1776–1783.PubMed

50.

Chen, X., Liu, S., Hou, Y., et al. (2004). MicroPET imaging of breast cancer av-integrin expression with ⁶⁴Cu-labeled dimeric RGD peptides. Molecular Imaging and Biology, 6, 350–359.PubMed

51.

Wu, Y., Zhang, X., Xiong, Z., et al. (2005). MicroPET imaging of glioma av-integrin expression using ⁶⁴Cu-labeled tetrameric RGD peptide. Journal of Nuclear Medicine, 46, 1707–1718.PubMed

52.

Thumshirn, G., Hersel, U., Goodman, S. L., & Kessler, H. (2003). Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry, 9, 2717–2725.PubMed

53.

Poethko, T., Schottelius, M., Thumshirn, G., Hersel, U., Herz, M., Henriksen, G., et al. (2004). Two-step methodology for high-yield routine radiohalogenation of peptides: ¹⁸F-labeled RGD and octreotide analogs. Journal of Nuclear Medicine, 45, 892–902.PubMed

54.

Poethko, T., Schottelius, M., Thumshirn, G., Herz, M., Haubner, R., Henriksen, G., et al. (2004). Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta, 92, 317–327.

55.

Montet, X., Montet-Abou, K., Reynolds, F., et al. (2006). Nanoparticle imaging of integrins on tumor cells. Neoplasia, 8(3), 214–222.PubMed

56.

Hu, G., Lijowski, M., Zhang, H., et al. (2007). Imaging of Vx-2 rabbit tumors with αvβ3- integrin-targeted ¹¹¹In nanoparticles. International Journal of Cancer, 120, 1951–1957.

57.

Balasubramanian, K., & Burghard, M. (2005). Chemically functionalized carbon nanotubes. Small, 1, 180–192.PubMed

58.

Lacerda, L., Bianco, A., Prato, M., & Kostarelos, K. (2006). Carbon nanotubes as nanomedicines: From toxicology to pharmacology. Advanced Drug Delivery Reviews, 58, 1460–1470.PubMed

59.

Liu, Z., Cai, W., He, L., et al. (2007). In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nature Nanotechnology, 2, 47–52.PubMed

60.

Singh, R., Pantarotto, D., Lacerda, L., et al. (2006). Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proceedings of the National Academy of Sciences of the United States of America, 103, 3357–3362.PubMed

61.

McDevitt, M. R., Chattopadhyay, D., Kappel, B. J., et al. (2007). Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of Nuclear Medicine, 48, 1180–1189.PubMed

62.

Caliceti, P., & Veronese, F. M. (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Advanced Drug Delivery Reviews, 55, 1261–1277.PubMed

63.

Wu, A. M., & Senter, P. D. (2005). Arming antibodies: Prospects and challenges for immunoconjugates. Nature Biotechnology, 23, 1137–1146.PubMed

64.

Introcaso, C. E., Hivnor, C., Cowper, S., & Werth, V. P. (2007). Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: A case series of nine patients and review of the literature. International Journal of Dermatology, 46(5), 447–452.PubMed

65.

Miller, J. C., Pien, H. H., Sahani, D., et al. (2005). Imaging angiogenesis: Applications and potential for drug development. Journal of the National Cancer Institute, 97(3), 172–187.PubMedCrossRef

66.

Spuentrup, E., & Botnar, R. M. (2006). Coronary magnetic resonance imaging: Visualization of vessel lumen and the vessel wall and molecular imaging of arteriotrombosis. European Radiology, 16, 1–14.PubMed

67.

Jaffer, F. A., & Weissleder, R. (2004). Seeing within: Molecular imaging of the cardiovascular system. Circulation Research, 94, 433–445.PubMed

68.

Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. (1998). Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nature Medicine, 4, 623–626.PubMed

69.

Winter, P. M., Caruthers, S. D., Kassner, A., et al. (2003). Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Research, 63, 5838–5843.PubMed

70.

Schmieder, A. H., Winter, P. M., Caruthers, S. D., et al. (2005). Molecular MR imaging of melanoma angiogenesis with αvβ3-targeted paramagnetic nanoparticles. Magnetic Resonance in Medicine, 53, 621–627.PubMed

71.

Thorek, D. L., Chen, A. K., Czupryna, J., & Tsourkas, A. (2006). Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Annals of Biomedical Engineering, 34, 23–38.PubMed

72.

Zhang, C., Jugold, M., Woenne, E. C., et al. (2007). Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Research, 67, 1555–1562.PubMed

73.

Daldrup-Link, H. E., Simon, G. H., & Brasch, R. C. (2006). Imaging of tumor angiogenesis: Current approaches and future prospects. Current Pharmaceutical Design, 12, 2661–2672.PubMed

74.

McDonald, D. M., & Choyke, P. L. (2003). Imaging of angiogenesis: From microscope to clinic. Nature Medicine, 9(6), 713–725.PubMed

75.

Bloch, S. H., Dayton, P. A., & Ferrara, K. W. (2004). Targeted imaging using ultrasound contrast agents. Progress and opportunities for clinical and research applications. IEEE Engineering in Medicine and Biology Magazine, 23, 18–29.PubMed

76.

Kaufmann, B. A., & Lindner, J. R. (2007). Molecular imaging with targeted contrast ultrasound. Current Opinion in Biotechnology, 18, 11–16.PubMed

77.

Ellegala, D. B., Leong-Poi, H., Carpenter, J. E., et al. (2003). Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvβ3. Circulation, 108, 336–341.PubMed

78.

Kumar, C. C., Nie, H., Rogers, C. P., et al. (1997). Biochemical characterization of the binding of echistatin to integrin αvβ3 receptor. Journal of Pharmacology and Experimental Therapeutics, 283, 843–853.PubMed

79.

Hughes, M. S., Marsh, J. N., Zhang, H., et al. (2006). Characterization of digital waveforms using thermodynamic analogs: Detection of contrast-targeted tissue in vivo. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 53, 1609–1616.PubMed

80.

Marsh, J. N., Partlow, K. C., Abendschein, D. R., Scott, M. J., Lanza, G. M., & Wickline, S. A. (2007). Molecular imaging with targeted perfluorocarbon nanoparticles: Quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound in Medicine & Biology, 33(6), 950–958.

81.

Ntziachristos, V., Yodh, A., Schnall, M., et al. (2000). Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proceedings of the National Academy of Sciences of the United States of America, 97, 2767–2772.PubMed

82.

Cuccia, D. J., Bevilacqua, F., Durkin, A. J., et al. (2003). In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration. Applied Optics, 42, 2940–2950.PubMed

83.

Bremer, C., Bredow, S., Mahmood, U., et al. (2001). Optical imaging of matrix metalloproteinase-2 activity in tumors: Feasibility study in a mouse model. Radiology, 221, 523–529.PubMed

84.

Chen, X., Conti, P. S., & Moats, R. A. (2004). In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Research, 64(21), 8009–8014.PubMed

85.

Jin, Z. H., Josserand, V., Foillard, S., Boturyn, D., Dumy, P., Favrot, M. C., et al. (2007). In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors. Molecular Cancer, 6, 41.PubMed

86.

von Wallbrunn, A., Holtke, C., Zuhlsdorf, M., Heindel, W., Schafers, M., & Bremer, C. (2007). In vivo imaging of integrin alpha v beta 3 expression using fluorescence-mediated tomography. European Journal of Nuclear Medicine and Molecular Imaging, 34(5), 745–754, Epub 2006 Nov 28.

87.

Cai, W., Hsu, A. R., Li, Z. B., & Chen, X. (2007). Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Research Letters, 2, 265–281.

88.

Michalet, X., Pinaud, F. F., Bentolila, L. A., et al. (2005). Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 307, 538–544.PubMed

89.

Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. (2005). Quantum dot bioconjugates for imaging, labelling and sensing. Nature Materials, 4, 435–446.PubMed

90.

Cai, W., Shin, D. W., Chen, K., et al. (2006). Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Letters, 6, 669–676.PubMed

91.

Levenson, R. M. (2004). Spectral imaging and pathology: Seeing more. Laboratory Medicine, 35, 244–251.

92.

Mansfield, J. R., Gossage, K. W., Hoyt, C. C., & Levenson, R. M. (2005). Autofluorescence removal, multiplexing, and automated analysis methods for in-vivo fluorescence imaging. Journal of Biomedical Optics, 10, 41207.PubMed

93.

Zimmer, J. P., Kim, S. W., Ohnishi, S., Tanaka, E., Frangioni, J. V., & Bawendi, M. G. (2006). Size series of small indium arsenide-zinc selenide core-shell nanocrystals and application to in vivo imaging. Journal of the American Chemical Society, 128, 2526–2527.PubMed

94.

Pradhan, N., Battaglia, D. M., Liu, Y., & Peng, X. (2007). Efficient, stable, small, and water-soluble doped ZnSe nanocrystal emitters as non-cadmium biomedical labels. Nano Letters, 7, 312–317.PubMed

95.

Mulder, W. J., Koole, R., Brandwijk, R. J., et al. (2006). Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Letters, 6, 1–6.PubMed

96.

Beer, A. J., Haubner, R., Goebel, M., et al. (2005). Biodistribution and pharmacokinetics of the αvβ3 selective tracer ¹⁸F Galacto-RGD in cancer patients. Journal of Nuclear Medicine, 46, 1333–1341.PubMed

97.

Beer, A. J., Haubner, R., Wolf, I., et al. (2006). PET-based human dosimetry of ¹⁸F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. Journal of Nuclear Medicine, 47, 763–769.PubMed

98.

Stangier, I., Wester, H. J., Schwaiger, M., & Beer, A. J. (2007). Comparison of standardised uptake values and distribution volume for imaging of avz3 expression in breast cancer patients with [¹⁸F]Galacto-RGD PET. Journal of Nuclear Medicine, 48(S2), 406, (abstract).

99.

Beer, A. J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A. L., et al. (2006). Positron emission tomography using [¹⁸F]Galacto-RGD identifies the level of integrin αvβ3 expression in man. Clinical Cancer Research, 12(13), 3942–3949.PubMed

100.

Beer, A. J., Grosu, A. L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., et al. (2007). [¹⁸F]Galacto-RGD PET for imaging of αvβ3 expression on neovasculature in patients with squamous cell carcinoma of the head and neck. Clinical Cancer Research, 13, 6610–6616.PubMed

101.

Beer, A. J., Lorenzen, S., Metz, S., Wester, H. J., & Schwaiger, M. (2007). Integrin avz3 expression and glucose metabolism do not correlate in primary and metastatic lesions in cancer patients: A PET study using [¹⁸F]Galacto-RGD and [¹⁸F]FDG. Journal of Nuclear Medicine, 48(S2), 30, (abstract).

Titel: Imaging of integrin αvβ3 expression
verfasst von: Ambros J. Beer
Markus Schwaiger
Publikationsdatum: 01.12.2008
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9158-3

Springer Medizin

Imaging of integrin αvβ3 expression

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents

Preface-imaging in cancer

Biography - Anthony F. Shields, M.D., Ph.D.

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

Imaging of tumor glucose utilization with positron emission tomography

The role of DNA synthesis imaging in cancer in the era of targeted therapeutics

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie